The Valley Desk

Clinical trial reportScience translational medicinePublished

A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma

12 of 43 authors shown in byline order.

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Clinical trial report
Venue
Science translational medicine
Published
Subject terms
Cell Line, Tumor; Humans; Glioblastoma; Brain Neoplasms; Neoplasm Recurrence, Local; Drug Resistance, Neoplasm; Adult; Aged; Middle Aged; Female; Male; Tumor Suppressor Protein p53
PubMed ID
39970230
PubMed Central ID
PMC11994224
Added to directory
Source checked

Report a correction or request removal